Galectin-3與MMP-9在膀胱尿路上皮細(xì)胞癌中的表達(dá)及臨床意義
本文選題:膀胱尿路上皮細(xì)胞癌 + 半乳糖凝集素-3。 參考:《安徽醫(yī)科大學(xué)》2014年碩士論文
【摘要】:目的通過檢測(cè)半乳糖凝集素-3(Galectin-3)和基質(zhì)金屬蛋白酶-9(MMP-9)在膀胱尿路上皮細(xì)胞癌(BUCC)組織中的表達(dá)情況,分析兩者與BUCC臨床病理參數(shù)的關(guān)系,,探討Galectin-3和MMP-9在BUCC的發(fā)生、發(fā)展及預(yù)后的臨床意義。 方法采用免疫組織化學(xué)鏈霉菌抗生物素蛋白-過氧化物酶(S-P)方法,對(duì)67例BUCC(其中T1期17例,T2期23例,T3期20例,T4期7例)和12例正常膀胱組織中Galectin-3和MMP-9的表達(dá)進(jìn)行檢測(cè),并計(jì)數(shù)BUCC腫瘤組織的微血管密度(MVD)。結(jié)合臨床病理數(shù)據(jù),應(yīng)用統(tǒng)計(jì)學(xué)方法分析兩者與BUCC的腫瘤大小、病理分級(jí)、臨床分期、淋巴轉(zhuǎn)移、復(fù)發(fā)性和MVD等,以及與BUCC患者的年齡、性別和術(shù)后生存率的關(guān)系。 結(jié)果BUCC組織中,Galectin-3和MMP-9陽(yáng)性表達(dá)率為62.69%和73.13%,分別高于在正常膀胱組織的16.67%和0.00%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);BUCC臨床分期及病理分級(jí)越高,兩者陽(yáng)性表達(dá)率越高,有淋巴結(jié)轉(zhuǎn)移者較無轉(zhuǎn)移者陽(yáng)性表達(dá)率高,復(fù)發(fā)者較初發(fā)者高,差異有統(tǒng)計(jì)學(xué)意義(P0.05);Galectin-3和MMP-9陽(yáng)性表達(dá)率在不同性別、不同年齡和不同腫瘤大小之間無明顯差異,無統(tǒng)計(jì)學(xué)意義(P0.05)。MMP-9在Galectin-3表達(dá)陽(yáng)性的BUCC中的陽(yáng)性表達(dá)率較Galectin-3陰性中的高;相應(yīng)的,Galectin-3在MMP-9表達(dá)陽(yáng)性的BUCC組織中的陽(yáng)性表達(dá)率較MMP-9陰性中的高。兩者在BUCC中表達(dá)呈正相關(guān),存在統(tǒng)計(jì)學(xué)意義(χ2=22.284,列聯(lián)系數(shù)r=0.500,P 0.05)。MVD在Galectin-3和MMP-9呈現(xiàn)陽(yáng)性表達(dá)的BUCC組織中高于陰性者,差異有統(tǒng)計(jì)學(xué)意義(P 0.05)。Galectin-3和MMP-9表達(dá)陽(yáng)性的患者術(shù)后5年生存率低于表達(dá)陰性者,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。 結(jié)論Galectin-3和MMP-9與BUCC病理學(xué)分級(jí)、臨床分期、淋巴結(jié)轉(zhuǎn)移及復(fù)發(fā)密切相關(guān),可能與BUCC的發(fā)生、進(jìn)展、侵犯及轉(zhuǎn)移有關(guān),且兩者可能存在某種協(xié)同效應(yīng);兩者對(duì)BUCC組織腫瘤血管生成可能具有某種上調(diào)作用,對(duì)BUCC發(fā)生及發(fā)展機(jī)制研究可能有科研價(jià)值;兩者與患者術(shù)后生存率密切相關(guān),可能成為BUCC手術(shù)治療的有效預(yù)后指標(biāo)。
[Abstract]:Objective to investigate the expression of Galectin-3 (galectin-3) and matrix metalloproteinase-9 (MMP-9) in bladder urinary tract epithelial cell carcinoma (BUCC), and to analyze the relationship between them and the clinicopathological parameters of BUCC, and to explore the occurrence of Galectin-3 and MMP-9 in BUCC. Clinical significance of development and prognosis. Methods the expression of Galectin-3 and MMP-9 in 67 cases of bucca (17 cases of T 1, 23 cases of stage T 3, 7 cases of phase 4 of T 3) and 12 cases of normal bladder tissues were detected by immunohistochemical streptomyces biotin-peroxidase S-P method. The microvessel density of BUCC tumor tissue was counted. Combined with clinicopathological data, the relationship between tumor size, pathological grade, clinical stage, lymphatic metastasis, recurrence and MVD, and age, sex and postoperative survival rate of BUCC patients were analyzed by statistical method. Results the positive expression rates of Galectin-3 and MMP-9 in BUCC were 62.69% and 73.13, respectively, which were higher than those in normal bladder tissue (16.67% and 0.005%, respectively). The higher the clinical stage and pathological grade were, the higher the positive expression rate was. The positive expression rate of Galectin-3 and MMP-9 in patients with lymph node metastasis was higher than that in patients with lymph node metastasis, and the positive rates of Galectin-3 and MMP-9 in patients with recurrent lymph nodes were higher than those without metastasis. There was no significant difference in the positive expression rates of Galectin-3 and MMP-9 between different genders, different ages and different tumor sizes. The positive expression rate of MMP-9 in Galectin-3 positive BUCC was higher than that in Galectin-3 negative BUCC, and the positive rate of MMP-9 positive BUCC was higher than MMP-9 negative. There was a positive correlation between them in BUCC and there was a significant difference between them (蠂 ~ 2, P = 22.284, r = 0.500 P 0.05).MVD). The positive expression of P 0.05).MVD in Galectin-3 and MMP-9 was higher than that in the negative ones. The 5-year survival rate of patients with positive expression of P 0.05).Galectin-3 and MMP-9 was significantly lower than that of patients with negative expression of P 0.05).Galectin-3 and MMP-9, and the difference was statistically significant (P 0.05). Conclusion Galectin-3 and MMP-9 are closely related to the pathological grading, clinical stage, lymph node metastasis and recurrence of BUCC, and may be related to the occurrence, progression, invasion and metastasis of BUCC, and there may be some synergistic effect between them. Both of them may have some up-regulation effect on tumor angiogenesis in BUCC tissues, and may be of scientific value in the study of the pathogenesis and development of BUCC, and they are closely related to the survival rate of the patients after operation, and may be an effective prognostic index for the treatment of BUCC.
【學(xué)位授予單位】:安徽醫(yī)科大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2014
【分類號(hào)】:R737.14
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 江忠清,朱鳳川,曲軍英,鄭秀,游彩玲;宮頸癌MMP-9表達(dá)與腫瘤血管生成、癌細(xì)胞增殖及侵襲轉(zhuǎn)移的關(guān)系[J];癌癥;2003年02期
2 凌海濱;徐勇;;尿生物標(biāo)志物檢測(cè)膀胱癌的進(jìn)展[J];國(guó)際泌尿系統(tǒng)雜志;2006年06期
3 周結(jié)學(xué),謝平;高復(fù)發(fā)性膀胱腫瘤VEGF、MVD研究現(xiàn)狀[J];江西醫(yī)學(xué)院學(xué)報(bào);2003年02期
4 趙斌;黃云超;;MMP-9與膀胱癌的研究進(jìn)展[J];昆明醫(yī)學(xué)院學(xué)報(bào);2008年S1期
5 陳偉;張方毅;陳洪德;李葉平;黃卡特;;Galectin-3蛋白在膀胱移行細(xì)胞癌中的表達(dá)及其意義[J];臨床泌尿外科雜志;2007年09期
6 王月生;鐘惟德;;現(xiàn)代膀胱癌發(fā)病因素的流行病學(xué)分析[J];現(xiàn)代泌尿生殖腫瘤雜志;2010年06期
7 賴麗琴;張紅;吳倩;秦蓉;;CD147、MMP-2 mRNA在胃癌組織中的表達(dá)及臨床意義[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2011年05期
8 陳啟光;楊琦;張哲;于秀月;單廣夷;孔垂?jié)?;Galectin-3在膀胱癌中的表達(dá)及臨床意義[J];中國(guó)醫(yī)科大學(xué)學(xué)報(bào);2010年09期
9 許克新,侯樹坤,杜志軍,白文俊 ,范丙申;檢測(cè)金屬基質(zhì)蛋白酶及其抑制物對(duì)判斷膀胱癌浸潤(rùn)和轉(zhuǎn)移的意義[J];中華泌尿外科雜志;2002年04期
10 王元天,孫穎浩,錢松溪;基質(zhì)金屬蛋白酶表達(dá)在膀胱癌侵襲轉(zhuǎn)移中的作用[J];中華泌尿外科雜志;2002年11期
本文編號(hào):1955586
本文鏈接:http://sikaile.net/yixuelunwen/mjlw/1955586.html